The Asia Pacific influenza vaccines market is expected to grow from US$ 1,688.07 million in 2022 to US$ 2,669.27 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2022 to 2028.
Emerging Economies to Fuel Asia Pacific Influenza Vaccines Market During Forecast Period
Leading players in the Asia Pacific influenza vaccines market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting their manufacturing capabilities. With the maturing of the region, players are shifting their focus to emerging economies. Due to less stringent regulations and data requirements, Asia Pacific has become a business-friendly and adaptable hub. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in upgrading the latest technologies in developing countries, which supports the inclination toward advanced vaccine development. Key producers of influenza vaccines in India and South Korea are expected to witness lucrative opportunities in the coming years due to the large patient pool and high prevalence of influenza, surge in healthcare infrastructure, rise in disposable income, and the surge of medical tourism in these countries.
Asia Pacific Influenza Vaccines Market Overview
Asia Pacific (APAC) is the fastest-growing regional market for influenza vaccines. The Asia Pacific influenza vaccines market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. Owing to the increase in government support and surveillance regarding vaccination against influenza, rise in investment by leading market players across the region, and increase in prevalence and incidence of influenza in this region. These factors are expected to propel the Asia Pacific influenza vaccines market in the coming years.
Asia Pacific Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Influenza Vaccines Market Segmentation
The Asia Pacific influenza vaccines market is segmented into vaccine type, virus type, technology, route of administration, target group, and country.
Based on vaccine type, the Asia Pacific influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.
Based on virus type, the Asia Pacific influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.
Based on technology, the Asia Pacific influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.
Based on route of administration, the Asia Pacific influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.
Based on target group, the Asia Pacific influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.
Based on country, the Asia Pacific influenza vaccines market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the market in 2022.
AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the Asia Pacific influenza vaccines market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,688.07 Million |
| Market Size by 2028 | US$ 2,669.27 Million |
| CAGR (2022 - 2028) | 6.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Vaccine Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Influenza Vaccines Market is valued at US$ 1,688.07 Million in 2022, it is projected to reach US$ 2,669.27 Million by 2028.
As per our report Asia Pacific Influenza Vaccines Market, the market size is valued at US$ 1,688.07 Million in 2022, projecting it to reach US$ 2,669.27 Million by 2028. This translates to a CAGR of approximately 6.9% during the forecast period.
The Asia Pacific Influenza Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Influenza Vaccines Market report:
The Asia Pacific Influenza Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Influenza Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Influenza Vaccines Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Influenza Vaccines Market
